The mitochondrial complex i inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism
暂无分享,去创建一个
P Champy | M. Ruberg | F. Darios | F. Medja | A. Lombès | A. Jousset | A. Laurens | R. Hocquemiller | P. Michel | G. Höglinger | E. Hirsch | M Ruberg | A. Lannuzel | A Lombès | P. Champy | A Lannuzel | P. P Michel | G. U Höglinger | A Jousset | F Medja | F Darios | C Gleye | A Laurens | R Hocquemiller | E. C Hirsch | C. Gleye | A. Lombès
[1] Alexis Elbaz,et al. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study , 1999, The Lancet.
[2] M. Caron,et al. Molecular characterization of the dopamine transporter. , 1993, Trends in pharmacological sciences.
[3] Jean Féger,et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.
[4] H. M. Geller,et al. 1‐Methyl‐4‐(2′‐Ethylphenyl)‐1,2,3,6‐Tetrahydropyridine‐ Induced Toxicity in PC12 Cells Is Enhanced by Preventing Glycolysis , 1992, Journal of neurochemistry.
[5] K. O’Malley,et al. The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.
[6] A. Storch,et al. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism , 2000, Journal of Neural Transmission.
[7] Charles Duyckaerts,et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. , 2002, Brain : a journal of neurology.
[8] S. Mandel,et al. Genes and oxidative stress in parkinsonism: cDNA microarray studies. , 2003, Advances in neurology.
[9] Todd B. Sherer,et al. An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.
[10] M. Esposti. Inhibitors of NADH-ubiquinone reductase: an overview. , 1998 .
[11] F. Hefti,et al. Toxicity of 1‐Methyl‐4‐Phenylpyridinium for Rat Dopaminergic Neurons in Culture: Selectivity and Irreversibility , 1990, Journal of neurochemistry.
[12] J. Tormo,et al. Specific interactions of monotetrahydrofuranic annonaceous acetogenins as inhibitors of mitochondrial complex I. , 1999, Chemico-biological interactions.
[13] Merle Ruberg,et al. Toxicity of Annonaceae for dopaminergic neurons: Potential role in atypical parkinsonism in Guadeloupe , 2002, Movement disorders : official journal of the Movement Disorder Society.
[14] Y. Agid,et al. The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures , 1992, Brain Research.
[15] P. R. Gilmore,et al. Glucose transport in primary cultured neurons , 1989, Journal of neuroscience research.
[16] J. McLaughlin,et al. Annonaceous acetogenins: recent progress. , 1999, Journal of natural products.
[17] W. Staines,et al. Immunohistochemical localization and quantification of glucose transporters in the mouse brain , 2002, Neuroscience.
[18] A. Schapira,et al. Mitochondrial involvement in Parkinson’s disease , 2002, Neurochemistry International.
[19] A. Privat,et al. Neuroprotection of cultured foetal rat hippocampal cells against glucose deprivation: are GABAergic neurons less vulnerable or more sensitive to TCP protection? , 1999, The European journal of neuroscience.
[20] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[21] S. Ochs,et al. INHIBITION OF GLYCERALDEHYDE‐3‐PHOSPHATE DEHYDROGENASE IN MAMMALIAN NERVE BY IODOACETIC ACID , 1971, Journal of neurochemistry.
[22] G I Bell,et al. Structure and function of mammalian facilitative sugar transporters. , 1993, The Journal of biological chemistry.
[23] E. Hirsch,et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy , 1985, Annals of neurology.
[24] Y. Agid,et al. Rescue of Mesencephalic Dopamine Neurons by Anticancer Drug Cytosine Arabinoside , 1997, Journal of neurochemistry.
[25] J. Barrett,et al. Cryopreservation of primary neurons for tissue culture , 1986, Brain Research.
[26] M. Fillenz,et al. Extracellular Brain Glucose Levels Reflect Local Neuronal Activity: A Microdialysis Study in Awake, Freely Moving Rats , 1992, Journal of neurochemistry.
[27] D. Brooks,et al. Atypical parkinsonism in Afro‐Caribbean and Indian origin immigrants to the UK , 2000, Movement disorders : official journal of the Movement Disorder Society.
[28] H. Miyoshi,et al. Essential structural factors of acetogenins, potent inhibitors of mitochondrial complex I. , 2002, Bioorganic & medicinal chemistry letters.
[29] J. Dartigues,et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[30] A. Godoy,et al. Expression of the hexose transporters GLUT1 and GLUT2 during the early development of the human brain , 1999, Brain Research.
[31] D. Choi. Ionic dependence of glutamate neurotoxicity , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[32] H. Freeze,et al. Studies of mannose metabolism and effects of long-term mannose ingestion in the mouse. , 2001, Biochimica et biophysica acta.
[33] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[34] L. Golbe,et al. Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.
[35] L. Netchiporouk,et al. Brain extracellular glucose assessed by voltammetry throughout the rat sleep–wake cycle , 2001, The European journal of neuroscience.
[36] M. Vila,et al. Free radical and nitric oxide toxicity in Parkinson's disease. , 2003, Advances in neurology.
[37] Samuel M. Goldman,et al. EPIDEMIOLOGY OF PARKINSON'S DISEASE , 1996, Neurologic Clinics.
[38] H. Shimada,et al. The localisations in liposomal membranes of the tetrahydrofuran ring moieties of the annonaceous acetogenins, annonacin and sylvaticin, as determined by 1H NMR spectroscopy. , 1998, Pharmacological research.
[39] A. Benabid,et al. Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition , 1996, Neuroscience Letters.
[40] K. Lange. Role of microvillar cell surfaces in the regulation of glucose uptake and organization of energy metabolism. , 2002, American journal of physiology. Cell physiology.
[41] Y. Agid,et al. Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy , 1995, Neurology.
[42] S. Snyder,et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[43] M. Ruberg,et al. Noradrenaline provides long‐term protection to dopaminergic neurons by reducing oxidative stress , 2001, Journal of neurochemistry.
[44] M. Ruberg,et al. Survival promotion of mesencephalic dopaminergic neurons by depolarizing concentrations of K+ requires concurrent inactivation of NMDA or AMPA/kainate receptors , 2001, Journal of neurochemistry.
[45] M. Ruberg,et al. Activation of the mitogen-activated protein kinase (ERK(1/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. , 2002, Molecular pharmacology.